STOCK TITAN
  1. Home
  2. Sec-filings
  3. BPTH
  4. [8-K] BIO-PATH HOLDINGS, INC. Reports Material Event

Bio-Path plans crypto treasury and judgment deal

Bio-Path Holdings disclosed several strategic changes and capital-related steps.

Filing Impact
(High)
Filing Sentiment
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

Bio-Path Holdings disclosed several strategic changes and capital-related steps. The company issued a shareholder update announcing a growth-focused repositioning, brought on new scientific advisors, engaged advisors to connect with strategic and financial investors, and canceled a previously approved 1-for-30 reverse stock split.

The Board approved a “digital asset treasury 2.0” program using AI to trade and accumulate multiple L1 and L2 blockchains and authorized opening an account with Coinbase or similar exchanges to buy, sell, and hold cryptocurrencies acquired through various channels. The Board also approved assigning to the company up to $10,000,000 of a $57,903,750 judgment, plus stated interest amounts, previously awarded to CEO Vikram Grover, with consideration to be paid in company securities when the judgment is monetized, aiming for accretion to shareholders. The company cautions there is no assurance Mr. Grover will obtain custodianship needed to complete related transactions.

Positive

  • None.

Negative

  • None.

Insights

Bio-Path adds a crypto-focused treasury plan and links to a large judgment, but execution and timing remain uncertain.

Bio-Path’s approval of a digital asset treasury 2.0 program moves part of its balance-sheet strategy into AI-driven trading of L1 and L2 blockchain assets through platforms such as Coinbase. This introduces potential new return sources but also exposes the company to digital asset price and regulatory volatility.

The Board’s approval to assign up to $10,000,000 of a $57,903,750 court judgment to the company, with payment in notes, preferred stock, or common shares once monetized, could eventually provide non-operating value. However, the company explicitly notes there is no assurance CEO Vikram Grover will secure custodianship necessary to execute transactions, so any benefit depends on future legal and monetization outcomes.

Judgment amount $57,903,750 Judgment awarded 12/05/2023 to CEO Vikram Grover
Judgment portion assigned Up to $10,000,000 Portion approved for assignment to Bio-Path Holdings
Pre-judgment interest $6,781,877.57 Pre-judgment interest related to the judgment
Reverse split ratio 1-for-30 Previously approved reverse stock split, now canceled
Case number 1:21-CV-05054 U.S. District Court, Northern District of Illinois
digital asset treasury 2.0 financial
"approved the launch of a digital asset treasury 2.0 (DAT 2.0) using AI"
L1 and L2 blockchains technical
"using AI to trade and accumulate multiple L1 and L2 blockchains"
centralized exchanges financial
"with similar well capitalized centralized exchanges for the purpose of buying, selling"
A centralized exchange is a trading platform run by a company that matches buyers and sellers, holds customer assets, and enforces rules much like a traditional bank or stock exchange. For investors, it matters because the operator controls custody and security of funds, sets fees and trading rules, and faces regulatory oversight, so trustworthiness and operational risk directly affect access, costs, and safety of investments.
Control Shareholder regulatory
"our Board of Directors and Control Shareholder approved the launch"
judgment regulatory
"assignment to the Company of up to $10,000,000.00 of a $57,903,750.00 judgment"
A judgment is a formal decision issued by a court or tribunal that resolves a legal dispute, often ordering one party to pay damages, stop certain actions, or comply with specific terms. For investors it matters because judgments can create direct financial liabilities, affect a company’s reputation or operations, and influence future cash flow and risk—similar to a final referee call that forces a team to change its game plan and budget.

FAQ

What strategic updates did Bio-Path Holdings (BPTH) announce in this 8-K?
Bio-Path announced a growth-focused repositioning, added new scientific advisors, engaged advisors for introductions to strategic and financial investors, and canceled a previously approved 1-for-30 reverse stock split, signaling a shift in strategy and capital structure planning.

What is Bio-Path Holdings’ new digital asset treasury 2.0 (DAT 2.0) program?
DAT 2.0 is a Board-approved initiative using AI to trade and accumulate multiple L1 and L2 blockchains with growing on-chain revenues and tokenomics. It includes opening accounts with Coinbase or similar exchanges to buy, sell, and hold cryptocurrencies acquired through several potential sources.

How does the Coinbase relationship factor into Bio-Path Holdings’ DAT 2.0 plan?
The Board authorized opening an account with Coinbase or another well-capitalized centralized exchange. This account would facilitate buying, selling, and holding cryptocurrencies obtained via open-market purchases, outside investment, customer payments, or strategic transactions under the DAT 2.0 approach.

What risks did Bio-Path highlight regarding the judgment linked to CEO Vikram Grover?
Bio-Path cautioned there can be no assurances Vikram Grover will successfully obtain custodianship over NSAV and related parties. Without that custodianship, executing a transaction or series of transactions with the company tied to the judgment may not occur as contemplated.

Did Bio-Path Holdings change its previously planned reverse stock split?
Yes. Bio-Path canceled a previously approved 1-for-30 reverse stock split as part of a broader shareholder update. The update also described repositioning to support growth, adding scientific advisors, and engaging advisors for introductions to strategic and financial investors.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
false 0001133818 0001133818 2026-05-14 2026-05-14 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

 

FORM 8-K

 

CURRENT REPORT PURSUANT

TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

 

Date of report (Date of earliest event reported): May 14, 2026

 

BIO-PATH HOLDINGS, INC.

(Exact name of registrant as specified in its charter)

 

Wyoming   001-36333   87-0652870

(State or other jurisdiction

of incorporation)

   (Commission File Number)   (IRS Employer Identification No.)

 

 

625 Stanwix St. #2407, Pittsburgh, PA   15222
(Address of principal executive offices)   (Zip Code)

 

(630) 708-0750

(Registrant’s Telephone Number, Including Area Code)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol   Name of each exchange on which registered
Common Stock, par value $0.001 per share   BPTH   OTC Pink

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

  
 

Bio-Path Holdings, Inc. is referred to herein as “Bio-Path”, “we”, “us”, or “the Company”.

 

Ite, 7.1 Regulation FD Disclosure

 

On May 14, 2026, we issued a shareholder update and announced repositioning to support growth, added scientific advisors, engaged advisors for introductions to strategic and financial investors, and canceled a previously approved 1-30 reverse split. The press release is included herein as Exhibit 10.1.

 

Item 8.1 Other Events.

 

On May 25, 2026, our Board of Directors and Control Shareholder approved the launch of a digital asset treasury 2.0 (DAT 2.0) using AI to trade and accumulate multiple L1 and L2 blockchains with growing on chain revenues and tokenomics. The Board further approved the opening of an account with CEX operator Coinbase or with similar well capitalized centralized exchanges for the purpose of buying, selling, and holding cryptocurrencies obtained by the Company through open-market purchases, outside investment, customer payments and/or strategic transactions.

 

On May 25, 2026, our Board approved the assignment to the Company of up to $10,000,000.00 of a $57,903,750.00 judgment (excluding pre-judgment interest of $6,781,877.57 and estimated post-judgment interest of several million dollars) awarded 12/05/2023 to our CEO, Vikram Grover, by the United States District Court for the Northern District of Illinois Civil Action No. 1:21-CV-05054 in Vikram Grover v. Net Savings Link, Inc. (OTC: NSAV; former operator of a crypto currency exchange and token creation platform) et al. Consideration will be paid in Company Notes, Preferred Stock or Common Shares at structures and prices to be determined when and as the Judgment is monetized with the intent of accretion to shareholders. There can be no assurances Mr. Grover will successfully obtain custodianship over NSAV et al. in order to effect a transaction or series of transactions with us. A copy of the final Court Order is included herein as Exhibit 10.2.

 

Exhibit No.   Description
     
10.1   Bio-Path Shareholder Update Press Release – 05/14/2026
10.2   Judgment - U.S. Northern District Illinois Case No. 1:21-CV-05054 – 09/05/2024
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

 2 
 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this Current Report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  BIO-PATH HOLDINGS, INC.
   
Dated: May 26, 2026  By: /s/ Vikram Grover
    Vikram Grover
    Chief Executive Officer, Chief Financial Officer and Director

 

 3 
 

 

Source: View Original Filing on SEC EDGAR

Filing Exhibits & Attachments

5 documents

Other Documents